The content on this site is intended for healthcare professionals only
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
16 Apr 2021
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
16 Apr 2021
CheckMate 9LA: First-line nivolumab, ipilimumab and 2 cycles chemotherapy vs 4 c...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
16 Apr 2021
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...
Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
16 Apr 2021
Efficacy and safety of selpercatinib in RET fusion-positive cancers other than l...
Prof Vivek Subbiah - MD Anderson Cancer Center, Houston, USA
13 Apr 2021
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
9 Apr 2021
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
9 Apr 2021
Cemiplimab plus ipilimumab for advanced NSCLC
Prof Byoung Yong Shim - The Catholic University of Korea, Suwon, South Korea
7 Apr 2021
Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small ...
Dr Erminia Massarelli - City of Hope, Duarte, USA
1 Apr 2021
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
29 Mar 2021
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 inserti...
Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passa...
29 Mar 2021
Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC i...
Prof Andrea Filippi - University of Pavia, Pavia, Italy
26 Mar 2021
